Avenciguat

It’s only fair to share… Avenciguat, 1579514-06-9 BI-685509, 582.7 g/mol, C34H38N4O5 UNII ZA7KTB4PSP 5-ethoxy-1-[6-[3-methyl-2-[[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]pyridin-2-yl]pyrazole-4-carboxylic acid Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD). Avenciguat is under …

VALILTRAMIPROSATE

It’s only fair to share… VALILTRAMIPROSATE 1034190-08-3 Molecular Weight 238.30 Formula C8H18N2O4S CAS No. 1034190-08-3 ALZ-801Synonyms: valiltramiprosate, NRM-8499, homotaurine prodrug, 3-APS This is a prodrug of homotaurine, a modified amino acid previously developed under the names tramiprosate and Alzhemed™. ALZ-801 is converted to homotaurine in vivo, but is more easily absorbed and lasts longer in the blood than …

VICATERTIDE

It’s only fair to share… VICATERTIDE 1251838-01-3 L-Leucyl-L-glutaminyl-L-valyl-L-valyl-L-tyrosyl-L-leucyl-L-histidine C42H66N10O10 L-Histidine, L-leucyl-L-glutaminyl-L-valyl-L-valyl-L-tyrosyl-L-leucyl- (ACI) 871.04 SB-01, HY-P5542, CS-0887146 (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Vicatertide is a TGF beta-1 inhibitor[1]. KR983182  SEQ ID NO: 1 (LQVVYLH: SEQ ID NO: 1) <Example 1> Preparation of peptides A peptide having the amino acid sequence of SEQ ID NO: 1 (LQVVYLH: SEQ ID NO: 1) was produced …

Vorbipiprant

It’s only fair to share… Vorbipiprant, CR6086 1417742-86-9 4-[1-[[[(5R)-6-[[4-(Trifluoromethyl)phenyl]methyl]-6-azaspiro[2.5]oct-5-yl]carbonyl]amino]cyclopropyl]benzoic acid Benzoic acid, 4-[1-[[[(5R)-6-[[4-(trifluoromethyl)phenyl]methyl]-6-azaspiro[2.5]oct-5-yl]carbonyl]amino]cyclopropyl]- Molecular Weight 472.50 Formula C26H27F3N2O3 Vorbipiprant (CR6086) is an EP4 receptor antagonist, serving as a targeted immunomodulator. Thus, Vorbipiprant is also a potential immune checkpoint inhibitor, to turn cold tumors into hot tumors. Vorbipiprant also antagonizes PGE2-stimulated cAMP production (IC50=22 nM). Vorbipiprant exhibit striking …

ATUZAGINSTAT

It’s only fair to share… ATUZAGINSTAT, COR388 cas 2211981-76-7 Cyclopentanecarboxamide, N-[(1S)-5-amino-1-[2-(2,3,6-trifluorophenoxy)acetyl]pentyl]- Cyclopentanecarboxamide, n-((1s)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-N-((3s)-7-amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide C19H25F3N2O3 386.415 UNII-DGN7ROZ8EN You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. Known as gingipains, these proteases penetrate gingival tissue and …

Votoplam

It’s only fair to share… Votoplam CAS 2407849-89-0 Molecular Formula C21H25N9O Molecular Weight 419.4829 PHENOL, 2-(3-(2,2,6,6-TETRAMETHYL-4-PIPERIDINYL)-3H-1,2,3-TRIAZOLO(4,5-C)PYRIDAZIN-6-YL)-5-(2H-1,2,3-TRIAZOL-2-YL)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(triazol-2-yl)phenol UNII D7EZ7B585X Votoplam is a gene splicing modulator, used to inhibit Huntington’s disease. Target: DNA/RNA SynthesisPathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive …

Atilotrelvir

It’s only fair to share… Atilotrelvir, BDBM622370, GST-HG171 2850365-55-6, ALIGOS THERAPEUTICS, INC 511.5 C24H32F3N5O4 (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide Spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide, N-[(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-2-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-, (1S,3S,4R)- Atilotrelvir (GST-HG171) is antiviral agent, can inhibit coronavirus, picornavirus and norovirus infection. SCHEME SYNTHESIS Patents are available for this chemical structure: https://patentscope.wipo.int/search/en/result.jsf?inchikey=GTRJFXDJASEGSW-KBCNZALWSA-N PATENT US20230312571, Embodiment 11 PATENT WO2023043816 EX 50 [0312] To a stirred mixture of (1R,4S,6S)-5-(tert-butoxycarbonyl)-5-azaspiro[bicyclo[2.2.1]heptane-2,1′-cyclopropane]-6-carboxylic acid (120 mg, 0.449 …

Zamaporvint

It’s only fair to share… Zamaporvint RXC004, PHASE 2 1H-IMIDAZOLE-1-ACETAMIDE, 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)- 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)-1H-IMIDAZOLE-1-ACETAMIDE UNII M56M7CHN8E Molecular Weight 439.39 Formula C21H16F3N7O CAS No. 1900754-56-4 Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and …

ATICAPRANT

It’s only fair to share… ATICAPRANT JNJ-67953964, WHO 10582 1174130-61-0 BENZAMIDE, 4-(4-(((2S)-2-(3,5-DIMETHYLPHENYL)-1-PYRROLIDINYL)METHYL)PHENOXY)-3-FLUORO- C26H27FN2O2,  418.512 Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder.[2][3][4] A regulatory application for approval of the medication is expected to be submitted by 2025.[2] Aticaprant is taken by mouth.[1] Side effects of aticaprant include itching, …

ZASTAPRAZAN

It’s only fair to share… ZASTAPRAZAN 2133852-18-1 362.5 g/mol, C22H26N4O JAQBO; JP-1366; OCN-101; Zastaprazan citrate – Onconic Therapeutics, UNII-W9S9KZX5MD Highest Development Phases Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. SCHEME Patent WO2018008929 PATENT KR1777971  //////////ZASTAPRAZAN, JAQBO, JP-1366, OCN-101, Zastaprazan citrate, Onconic Therapeutics, …